Home page > Europe and Health | Health, wealth and equity | Health friendly research and innovation | EU Funding and programmes | Irish Presidency priorities


Please find all related articles below.

Open letter on trilogue negotiations on EU’s Framework Programme for Research and Innovation (2014-2020) Horizon 2020

EPHA, together with 12 other organisations, signed an open letter urging trialogue decision makers to, though the adoption of appropriate licensing conditions, ensure global access to lifesaving medical innovations developed under the [EU Framework Programme for research and Innovation Horizon 2020. >http://ec.europa.eu/research/horizo...] In this letter, the signatory organisations stated that " any publicly funded medical product -be it a drug, vaccine or medical diagnostic- should be (...)

[Joint Press Statement] Access to medicines in Europe: The EU cannot save banks while sacrificing people’s health

Brussels, 17 May – In a seminar hosted yesterday by the Group of the Progressive Alliance of Socialists & Democrats (S&D) in the European Parliament and the Member of the European Parliament (MEP) Alejandro Cercas (S&D, Spain), six MEPs from various political groups (1) along with representatives of governments, leading academics, researches and public health organisations (2) met to raise awareness about one of the most alarming issues that European healthcare systems (...)

[EPHA Briefing] Access to Medicines in Europe in Times of Austerity

When discussing the topic of access to medicines in the context of the economic crisis we have to consider three determinants: affordability and availability, in terms of access to medicines, and innovation in terms of developing new methods of assuring best possible health outcomes. AFFORDABILILTY Usually, health expenditures are mostly covered by public funding and supplemented by private spending. The economic crisis has forced public expending to be cut making patient co-payment (...)

[Seminar report] Can EU Citizens Afford Their Medicines?

This high level meeting revolved around various political processes linked to the economic crisis. Some of the topics discussed include implementation of the Europe 2020 strategy, as well as pharmaceutical legislation for ensuring that people living in Europe have access to a wide range of quality and affordable medicines. The meeting hosted by Mr Alejandro Cercas, MEP (Spain,S&D) and by the Socialists and Democrats in the European Parliament (S&D Group) served to assess the impact (...)

Public consultation on Declaration of Helsinki on medical research involving human subjects

A two-month public consultation (15 April to 15 June 2013) on the World Medical Association’s Declaration of Helsinki on medical research involving human subjects has been launched by the World Medical Association. A revised version of the Declaration is available on the WMA website. This consultation is of particular interest in the context of the ongoing revision of the Clinical Trials legislation. Please click here for detailed information on the consultation process The (...)

Clinical trials: Exploring the limits of transparency

Glenis Willmott MEP (S&D, UK) took the initiative to bring together experts to discuss the extent to which more transparency could be workable in non-commercial clinical trials. The debate, which took place in the European Parliament on 10 April, served to present the key arguments for and against increased transparency in the context of administrative and data reporting requirements for academic researchers and patient safety. EPHA’s Position on Clinical Trials urges political (...)

[EPT] Medical devices - Regulation (recast) - Medical devices and in vitro diagnostic medical devices (17 April 2013)

Medical devices and in vitro diagnostic medical devices. The term “medical device” covers an extremely diverse range of healthcare instruments – from simple bandages and dressings to tongue depressors, medical thermometers and blood sugar meters to pacemakers and life-supporting products, as well as eHealth devices which communicate remotely. The medical devices industry constitutes a key sector for healthcare. It is one of the most dynamic sectors, improving and saving (...)

EPHA report expert workshop on future of public health research

On January, EPHA attended a workshop on the future of European public health research. This workshop was part of the on-going work of an Expert Group, whose purpose is to take stock of the benefits, challenges and limitations of EU-funded public health research. Among other goals, this event was aimed to assess the impact of Community funded research activities in the field of public health. Another objective of the workshop was to identify priorities for future research together with (...)

Medical Devices at EU Socialists & Democrats Workshop: an evolving debate

On 19 March 2013 a workshop on medical devices took place in the European Parliament to continue discussions over the legislative proposal presented by the European Commission in September 2012. The workshop was organised by the S&D Group (Group of the Progressive Alliance of Socialists and Democrats in the European Parliament) and was chaired by the Rapporteur for the Medical Devices report, Dagmar Roth-Behrendt MEP (Germany, S&D). The discussion over the two proposals on Medical (...)

European Parliament Civil Liberties Committee discusses amendments to the General Data Protection Regulation (GDPR)

The European Parliament’s committee for Civil Liberties, Justice and Home Affairs (LIBE) held a discussion on Wednesday 20 March 2013 on the amendments submitted to the General Data Protection Regulation. The discussion was held in the presence of the European Data Protection Supervisor (EDPS), Peter Hustinx, and the chairman of the Article 29 Working Party, Jakob Kohnstamm. Jan Albrecht MEP (Greens/EFA, Germany), rapporteur of the file, opened discussions by informing the Committee (...)